Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

PURPOSE: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II studies: vandetanib versus gefitinib (study 3), docet...

Повний опис

Бібліографічні деталі
Автори: Hanrahan, E, Ryan, A, Mann, H, Kennedy, S, Langmuir, P, Natale, R, Herbst, R, Johnson, B, Heymach, J
Формат: Journal article
Мова:English
Опубліковано: 2009

Схожі ресурси

Схожі ресурси